Alexandra Pearce - ABIVAX Socit Vice President and Head of Regulatory Affairs

All Insiders . USA . 
Stock . ABIVAX Socit Anonyme . Stakeholders . Insider . Alexandra Pearce
AAVXF Stock  USD 11.05  0.00  0.00%   

President

Dr. Alexandra Pearce was appointed as Vice President and Head of Regulatory Affairs of the Company., effective May 21, 2018 since 2018.
Tenure 6 years
Professional MarksPh.D
Phone33 1 53 83 08 41
Webhttps://www.abivax.com
Pearce joins ABIVAX from Viramal, where she served as Chief Operations Officer and Head of Regulatory Affairs. Previously, she held roles as Executive Vice President and Head of Global Regulatory Affairs for Glenmark, responsible for regulatory strategy, drug development and the successful commercialization of all inhouse and inlicensed products spanning 80 countries. Prior to this, as Executive Director, Global Regulatory Affairs and Safety at Amgen, she was responsible for developing and executing global regulatory strategies for early pipeline molecules across all therapeutic areas. Before joining Amgen, Dr. Pearce was the Global Regulatory Leader and Director of Worldwide Regulatory Strategy at Pfizer. In this role, Dr. Pearce was accountable for current and emerging business interests for products within the cardiovascular portfolio, as well as serving as Pfizer regulatory liaison with the FDA

ABIVAX Socit Management Efficiency

The company has return on total asset (ROA) of (0.4368) % which means that it has lost $0.4368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.8647) %, meaning that it generated substantial loss on money invested by shareholders. ABIVAX Socit's management efficiency ratios could be used to measure how well ABIVAX Socit manages its routine affairs as well as how well it operates its assets and liabilities.
ABIVAX Socit Anonyme has accumulated 53.45 M in total debt with debt to equity ratio (D/E) of 8.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ABIVAX Socit Anonyme has a current ratio of 1.99, which is within standard range for the sector. Debt can assist ABIVAX Socit until it has trouble settling it off, either with new capital or with free cash flow. So, ABIVAX Socit's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ABIVAX Socit Anonyme sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ABIVAX to invest in growth at high rates of return. When we think about ABIVAX Socit's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

PRESIDENT Age

Jennifer KissnerOUTLOOK THERAPEUTICS INC
N/A
Michael MathewsHeron Therapeuti
61
Yaron NaosProtalix Biotherapeutics
60
David SzekeresHeron Therapeuti
50
Elizabeth YamashitaOUTLOOK THERAPEUTICS INC
63
Alicia TozierOUTLOOK THERAPEUTICS INC
N/A
Sean RistineHeron Therapeuti
54
Thomas OttoboniHeron Therapeuti
65
ABIVAX Socit Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. The company was incorporated in 2013 and is headquartered in Paris, France. Abivax Sa is traded on OTC Exchange in the United States. ABIVAX Socit Anonyme [AAVXF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity-12.86
Return On Asset-0.44

ABIVAX Socit Anonyme Leadership Team

Elected by the shareholders, the ABIVAX Socit's board of directors comprises two types of representatives: ABIVAX Socit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABIVAX. The board's role is to monitor ABIVAX Socit's management team and ensure that shareholders' interests are well served. ABIVAX Socit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABIVAX Socit's outside directors are responsible for providing unbiased perspectives on the board's policies.
Didier Blondel, CFO, Board Secretary
Alain Chevallier, Advisor
Philippe MD, Founder Director
Regina Jehle, VP Communications
Prof Ehrlich, Chief Officer
Paul Gineste, VP Operations
Anne Pascard, HR Mang
Raquel Lizarraga, Investor Mang
Pierre MBA, Chief Devel
Alexandra Pearce, Vice President and Head of Regulatory Affairs

ABIVAX Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ABIVAX Socit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-12.86
Return On Asset-0.44
Operating Margin4.66 %
Current Valuation165.28 M
Shares Outstanding22.3 M
Shares Owned By Insiders4.67 %
Shares Owned By Institutions57.27 %
Price To Earning(7.88) X
Price To Book27.57 X
Price To Sales20.65 X

Currently Active Assets on Macroaxis

FFord Motor
GOOGAlphabet Inc Class C
CRMSalesforce
VVisa Class A
FFord Motor

Other Information on Investing in ABIVAX Pink Sheet

ABIVAX Socit financial ratios help investors to determine whether ABIVAX Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABIVAX with respect to the benefits of owning ABIVAX Socit security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY